A broader importance of NOPR to the future of nuclear imaging.

In their article published in this issue of The Journal of Nuclear Medicine (1), Hillner and coauthors once again emerge from the trove of data that is the National Oncologic PET Registry (NOPR) with valuable insights. This time, the investigators turned their attention to 7 cancers, plus a hodgepodge of rare tumors, for which Medicare still does not cover the use of PET for restaging or suspected recurrence or for evaluating patients’ response to treatment, except for PET facilities participating in Medicare’s coverage-with-evidence-development (CED) program. The principal finding of Hillner et al. is that, in comparing data accrued during 2006–2009